Personalized Medicine: Recent Progress in Cancer Therapy

Patient-derived xenograft models—the future of personalised cancer treatment

(2020) Jenna Bhimani et al.   BRITISH JOURNAL OF CANCER

Cancer Genome Evolutionary Trajectories in Metastasis

(2020) Nicolai J. Birkbak et al.   CANCER CELL

New clinical trial designs in the era of precision medicine

(2019) Elena Garralda et al.   Molecular Oncology

Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial

(2019) O Trédan et al.   ANNALS OF ONCOLOGY

Towards precision oncology for anti-HER2 blockade in gastroesophageal adenocarcinoma

(2019) V Gambardella et al.   ANNALS OF ONCOLOGY

The current state of molecular testing in the treatment of patients with solid tumors, 2019

(2019) Wafik S. El‐Deiry et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) patients (pts).

(2019) Teresa Macarulla Mercade et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study

(2019) Jason K. Sicklick et al.   NATURE MEDICINE

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

(2019) Jordi Rodon et al.   NATURE MEDICINE

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

(2019) Fabrice André et al.   NEW ENGLAND JOURNAL OF MEDICINE

TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma

(2019) Lipika Goyal et al.   Cancer Discovery

A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas

(2019) Chia-Chi Lin et al.   BRITISH JOURNAL OF CANCER

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

(2019) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

(2019) Yohann Loriot et al.   NEW ENGLAND JOURNAL OF MEDICINE

FGF401, a first-in-class highly selective and potent FGFR4 inhibitor for the treatment of FGF19-driven hepatocellular cancer

(2019) Andreas Weiss et al.   MOLECULAR CANCER THERAPEUTICS

Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers

(2019) Aparna R. Parikh et al.   NATURE MEDICINE

Phase I trials as valid therapeutic options for patients with cancer

(2019) Jacob J. Adashek et al.   Nature Reviews Clinical Oncology

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

(2019) Scott Kopetz et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma

(2019) Richard D Kim et al.   Cancer Discovery

Breast cancer

(2019) Nadia Harbeck et al.   Nature Reviews Disease Primers

NTRK-Fusions – A new kid on the block

(2019) Bruno Märkl et al.   PATHOLOGY RESEARCH AND PRACTICE

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

(2019) Lillian M. Smyth et al.   Cancer Discovery

NRF2 and the Hallmarks of Cancer

(2018) Montserrat Rojo de la Vega et al.   CANCER CELL

Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer

(2018) Rona Yaeger et al.   CANCER CELL

Revolutionizing Precision Oncology through Collaborative Proteogenomics and Data Sharing

(2018) Henry Rodriguez et al.   CELL

Establishment of a Patient-Derived Tumor Xenograft Model and Application for Precision Cancer Medicine

(2018) Seiji Okada et al.   CHEMICAL & PHARMACEUTICAL BULLETIN

The NCI-MATCH trial and precision medicine in gynecologic cancers

(2018) Lisa Barroilhet et al.   GYNECOLOGIC ONCOLOGY

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

(2018) John D. Hainsworth et al.   JOURNAL OF CLINICAL ONCOLOGY

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy

(2018) Simona Soverini et al.   Molecular Cancer

The emerging clinical relevance of genomics in cancer medicine

(2018) Michael F. Berger et al.   Nature Reviews Clinical Oncology

The paradox of precision medicine

(2018) Jonathan Kimmelman et al.   Nature Reviews Clinical Oncology

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

(2018) Georgios Vlachogiannis et al.   SCIENCE

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations

(2018) Sumanta K. Pal et al.   Cancer Discovery

Precision dosing in clinical medicine: present and future

(2018) Thomas M. Polasek et al.   Expert Review of Clinical Pharmacology

Abstract 2160: MEN1611, a novel α-selective PI3K inhibitor in solid tumors

(2018) Giuseppe Merlino et al.   CANCER RESEARCH

First-in-human study of DS-6051b in patients (pts) with advanced solid tumors (AST) conducted in the US.

(2018) Kyriakos P. Papadopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

A randomised, double-blind, placebo-controlled phase IIa trial of AMG319 given orally as neoadjuvant therapy in patients with human papillomavirus (HPV) positive and negative head and neck squamous cell carcinoma (HNSCC).

(2018) Christian H.H Ottensmeier et al.   JOURNAL OF CLINICAL ONCOLOGY

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

(2018) David M. Hyman et al.   NATURE

NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer

(2018) Valentina Gambardella et al.   CLINICAL CANCER RESEARCH

Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer

(2018) Marcus D. Goncalves et al.   NEW ENGLAND JOURNAL OF MEDICINE

Is Precision Medicine an Oxymoron?

(2018) S. Gail Eckhardt et al.   JAMA Oncology

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses

(2017) Tony S.K. Mok et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

(2017) Toshihiko Doi et al.   LANCET ONCOLOGY

Functional precision cancer medicine—moving beyond pure genomics

(2017) Anthony Letai   NATURE MEDICINE

Tumour heterogeneity and resistance to cancer therapies

(2017) Ibiayi Dagogo-Jack et al.   Nature Reviews Clinical Oncology

Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition

(2017) Arlene Siefker-Radtke et al.   Nature Reviews Urology

A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer

(2017) Michael Michael et al.   Targeted Oncology

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

(2017) Christophe Massard et al.   Cancer Discovery

Modeling Development and Disease with Organoids

(2016) Hans Clevers   CELL

Proteogenomics connects somatic mutations to signalling in breast cancer

(2016) Philipp Mertins et al.   NATURE

Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution

(2015) Nicholas McGranahan et al.   CANCER CELL

Correction: First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

(2015)   CLINICAL CANCER RESEARCH

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials

(2015) Maria Schwaederle et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval

(2015) Denis L. Fontes Jardim et al.   JNCI-Journal of the National Cancer Institute

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

(2015) Christophe Le Tourneau et al.   LANCET ONCOLOGY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

(2015) Sandra M. Swain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval

(2015) Denis L. Fontes Jardim et al.   JNCI-Journal of the National Cancer Institute

Liquid Biopsies: Genotyping Circulating Tumor DNA

(2014) Luis A. Diaz et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

(2014) Ian E Krop et al.   LANCET ONCOLOGY

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

(2014) C. Bettegowda et al.   Science Translational Medicine

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

(2013) R. Dienstmann et al.   ANNALS OF ONCOLOGY

Luminal breast cancer: from biology to treatment

(2013) Michail Ignatiadis et al.   Nature Reviews Clinical Oncology

Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives

(2013) Maria Vittoria Dieci et al.   Cancer Discovery

Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

(2012) A.-M. Tsimberidou et al.   CLINICAL CANCER RESEARCH

BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group

(2012) Kathryn Alsop et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

(2011) A. M. Gonzalez-Angulo et al.   CLINICAL CANCER RESEARCH

Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping

(2011) D. R. Borger et al.   ONCOLOGIST

Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers

(2010) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE